Dova Pharmaceuticals Inc (NASDAQ:DOVA) insider Jason Hoitt sold 2,387 shares of Dova Pharmaceuticals stock in a transaction dated Monday, April 8th. The shares were sold at an average price of $8.77, for a total value of $20,933.99. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Shares of NASDAQ DOVA traded down $0.01 during midday trading on Wednesday, hitting $8.52. The stock had a trading volume of 198,489 shares, compared to its average volume of 176,513. The firm has a market capitalization of $240.78 million, a P/E ratio of -3.28 and a beta of 2.06. Dova Pharmaceuticals Inc has a 1-year low of $5.62 and a 1-year high of $35.33. The company has a debt-to-equity ratio of 0.18, a current ratio of 5.73 and a quick ratio of 5.51.
Dova Pharmaceuticals (NASDAQ:DOVA) last released its quarterly earnings results on Tuesday, March 5th. The company reported ($0.69) EPS for the quarter, topping the consensus estimate of ($0.77) by $0.08. The company had revenue of $2.84 million for the quarter, compared to analyst estimates of $3.48 million. On average, equities research analysts expect that Dova Pharmaceuticals Inc will post -2.31 EPS for the current fiscal year.
Several research firms have recently weighed in on DOVA. BidaskClub lowered Dova Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday. HC Wainwright set a $18.00 price objective on Dova Pharmaceuticals and gave the company a “buy” rating in a research note on Tuesday, March 5th. LADENBURG THALM/SH SH lifted their price objective on Dova Pharmaceuticals to $32.00 and gave the company a “buy” rating in a research note on Tuesday, December 18th. They noted that the move was a valuation call. Finally, JPMorgan Chase & Co. lowered Dova Pharmaceuticals from an “overweight” rating to an “underweight” rating and reduced their price objective for the company from $34.00 to $20.00 in a research note on Wednesday, January 23rd. One investment analyst has rated the stock with a sell rating, four have given a hold rating and four have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average target price of $29.57.
Dova Pharmaceuticals Company Profile
Dova Pharmaceuticals, Inc, a pharmaceutical company, focuses on acquiring, developing, and commercializing drug candidates for thrombocytopenia disease. The company's lead drug candidate is avatrombopag that has completed Phase III clinical trials for the treatment of thrombocytopenia in patients with chronic liver disease.
Further Reading: What is the Dow Jones Industrial Average (DJIA)?
Receive News & Ratings for Dova Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dova Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.